Oncotarget

Clinical Research Papers:

Relationship of Oct-4 to malignant stage: a meta-analysis based on 502 positive/high Oct-4 cases and 522 negative/low case-free controls

Beilong Zhong _, Yan Lin, Yingrong Lai, Fangfang Zheng, Xiaobin Zheng, Rijiao Huang, Weilin Yang and Zhenguang Chen

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:2143-2152. https://doi.org/10.18632/oncotarget.5737

Metrics: PDF 901 views  |   HTML 968 views  |   ?  


Abstract

Beilong Zhong1,*, Yan Lin2,*, Yingrong Lai3,*, Fangfang Zheng4, Xiaobin Zheng5, Rijiao Huang6, Weilin Yang7, Zhenguang Chen7,8,9,*

1Department of Thoracic Surgery, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong 519000, China

2Department of Breast Disease, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China

3Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

4Department of Pediatrics, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong 519000, China

5Department of Respiratory Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong 519000, China

6Department of Clinical Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong 519000, China

7Department of Cardiothoracic Surgery of East Division, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

8Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

9Lung Cancer Research Center of Sun Yat-sen University, Guangzhou, Guangdong 510080, China

*These authors have contributed equally to this work

Correspondence to:

Zhenguang Chen, e-mail: chenzhenguang@yahoo.com

Keywords: Oct-4, cancer staging, TNM staging, cancer grade of differentiation, meta-analysis

Received: May 28, 2015     Accepted: October 28, 2015     Published: November 09, 2015

ABSTRACT

Background: Octamer 4 (Oct-4), an important member of the POU domain transcription factor family, has been suggested to function as a master switch during differentiation of human somatic cells and more recently has come to be linked with neoplastic properties. The aim of this study was to evaluate the relationship between Oct-4 and cancer stage using a meta-analysis approach.

Materials and Methods: Relevant articles published as of May 2015 were retrieved from the following databases: PubMed, ISI Web of Knowledge, Embase, and Chinese National Knowledge Infrastructure (CNKI). The strengths of relationship for outcomes of interest were estimated based on odds ratios (ORs) and 95% confidence intervals (CIs).

Results: A total of 11 articles on Oct-4 and cancer staging that collectively included 502 positive/high Oct-4 cases and 522 negative/low case-free controls were chosen. Positive/high Oct-4 was significantly associated with cancer stage in several kinds of cancer. Specifically, positive/high Oct-4 was associated with cancer stage III/IV (fixed effects: OR = 1.53, 95% CI = 1.12–2.10), primary tumor (T3–4) (random effects: OR = 1.93, 95% CI = 0.99–3.77), and cancer grade of differentiation (intermediate-poor) (random effects: OR = 3.45, 95% CI = 1.5–7.61).

Conclusion: These findings suggest that positive/high Oct-4 is more strongly linked to stage III/IV cancer and cancer grade of differentiation, and is correlated with malignant characteristics that lead to poor prognosis in different types of cancer, especially in Asian. Given variability related to ethnicity and differences in cancer types, additional studies are warranted to establish the generalizability of our findings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5737